DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.
Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.
With so many PrEP candidates at risk, why aren’t more being prescribed a PrEP medication?
Uptake of PrEP use in the United States remains low despite significant HIV risk1
Nearly
1 million males were indicated for a PrEP medication by 2018

However, only 21% of these patients were prescribed a PrEP medication2
Of new HIV diagnoses in 2018,3
39%
WERE BLACK MSM
and
31%
WERELATINO MSM
Yet, in a CDC study of PrEP use among MSM at risk (n=4056), only4
6%
WERE BLACK MSM
and
8%
WERELATINO MSM
Help meet HIV risk head-on—talk to your appropriate patients about DESCOVY FOR PrEP®.
CDC=Centers for Disease Control and Prevention; MSM=men who have sex with men.